Stoke Therapeutics (STOK) Common Equity (2018 - 2026)

Stoke Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $394.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 12.8% year-over-year to $394.9 million; the TTM figure through Mar 2026 stood at $394.9 million (up 12.8% YoY), while the FY2025 annual figure was $352.5 million, up 53.9% from the prior year.
• Common Equity for Q1 2026 stood at $394.9 million, up from $352.5 million in the prior quarter.
• The five-year high for Common Equity was $394.9 million in Q1 2026, with the low at $140.3 million in Q1 2024.
• The 5-year median for Common Equity is $229.0 million (2024), against an average of $245.6 million.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 34.37% in 2024, then soared 149.44% in 2025.
• Stoke Therapeutics' Common Equity stood at $184.8 million in 2022, then fell by 13.68% to $159.6 million in 2023, then jumped by 43.53% to $229.0 million in 2024, then jumped by 53.9% to $352.5 million in 2025, then gained by 12.04% to $394.9 million in 2026.
• Business Quant data shows STOK's Common Equity at $394.9 million in Q1 2026, $352.5 million in Q4 2025, and $308.1 million in Q3 2025.